RVMD Stock: Price, Earnings History and SEC Filings
Revolution Medicines, Inc. (RVMD) last traded at $191.31, up 0.55% on the latest session and down 6.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-2.34 against an analyst estimate of $-1.93, a miss of 21.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RVMD earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-2.34 | $-1.93 | -21.24% |
| Mar 2026 | May 6, 2026 | $-2.29 | $-1.83 | -25.14% |
| Dec 2025 | Feb 25, 2026 | $-1.86 | $-1.56 | -19.23% |
| Sep 2025 | Nov 5, 2025 | $-1.61 | $-1.39 | -15.83% |
RVMD beat the analyst EPS estimate in 0 of its last 4 reported quarters. Source: Nasdaq.
How RVMD reacts to earnings
Across its last 8 earnings releases, RVMD moved 3.8% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-05 | After close | +0.26% |
| 2026-05-06 | After close | -5.67% |
| 2026-02-25 | After close | -1.06% |
| 2025-11-05 | After close | +3.44% |
| 2025-08-06 | After close | -4.69% |
| 2025-05-07 | After close | +11.29% |
| 2025-02-26 | After close | -3.51% |
| 2024-11-06 | After close | -0.54% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
RVMD financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $0 | -$1.1B | -$914M | – | $-5.95 |
| 2024 | $0 | -$600M | -$568M | – | $-3.58 |
| 2023 | $12M | -$436M | -$358M | -3768.3% | $-3.86 |
| 2022 | $35M | -$249M | -$235M | -703.0% | $-3.08 |
| 2021 | $29M | -$187M | -$154M | -636.6% | $-2.57 |
| 2020 | $43M | -$108M | -$103M | -251.6% | $-2.01 |
| 2019 | $50M | -$48M | -$52M | -95.2% | – |
| 2018 | $20M | -$42M | -$286000 | -207.2% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for RVMD
- 8-K · Oct 13, 2026New financial obligation, Other events
- 8-K · Sep 1, 2026Material agreement, New financial obligation
- 8-K · Aug 26, 2026Other events
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 22, 2026Officer or director change, Shareholder vote
- 10-Q · May 6, 2026
- 8-K · May 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 27, 2026
- 8-K · Apr 17, 2026Material agreement, New financial obligation, Other events
Insider filing activity
RVMD insiders filed 19 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RVMD news
- Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"Oct 30, 2026 · finance.yahoo.com
- Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct CompetitionOct 29, 2026 · stocktwits.com
- NovoCure Sinks 5% Despite Guidance Raise as Pancreatic Cancer Launch Access Is “Significantly Limited”Oct 29, 2026 · tikr.com
- Could Revolution Medicines Be a Millionaire-Maker Stock?Oct 29, 2026 · fool.com
- Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?Oct 27, 2026 · fool.com
- Revolution Medicines to Participate in November 2026 Investor ConferencesOct 27, 2026 · finance.yahoo.com
- What 3 multibillion dollar biotechs still have to proveOct 27, 2026 · pharmavoice.com
- Cantargia Appoints Dr. Monic Stuart as Chief Medical OfficerOct 26, 2026 · finance.yahoo.com
About Revolution Medicines, Inc.
Revolution Medicines, Inc. (RVMD) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in DE. Its fiscal year ends in December.